Related Experiment Video

Updated: Jun 15, 2026

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E

Andrew C Hsieh1, Maria Costa, Ornella Zollo

  • 1School of Medicine and Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.

Cancer Cell
|March 16, 2010
PubMed

Insights

The 4EBP-eIF4E pathway, not rpS6, drives Akt-induced lymphoma. Inhibiting mTOR with PP242 effectively treats rapamycin-resistant tumors by targeting this pathway.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Akt signaling is crucial in lymphomagenesis.
  • mTOR pathway dysregulation contributes to cancer development.
  • Translational control plays a significant role in cancer initiation and progression.

Purpose of the Study:

  • To investigate the roles of downstream mTOR signaling components in Akt-driven lymphomagenesis.
  • To determine the therapeutic potential of targeting the 4EBP-eIF4E axis in cancer.

Main Methods:

  • Genetic dissection of mTOR pathway components.
  • Analysis of cap-dependent translation and cell growth.
  • Assessment of Mcl-1 expression and apoptosis.
  • Inhibition of mTOR using PP242 in a mouse model.

Main Results:

  • Phosphorylation of rpS6 is not essential for cancer formation.
  • The 4EBP-eIF4E axis significantly controls translation, cell growth, and tumor progression.
  • 4EBP-dependent Mcl-1 expression is critical for anti-apoptosis.
  • PP242 demonstrates therapeutic efficacy in rapamycin-resistant tumors by inhibiting mTORC1-dependent 4EBP-eIF4E hyperactivation.

Conclusions:

  • The 4EBP-eIF4E axis is a key mediator of Akt-driven lymphomagenesis.
  • Targeting the 4EBP-eIF4E pathway offers a therapeutic strategy for cancers, including rapamycin-resistant forms.
  • This study highlights the druggability of translational control in cancer treatment.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Strategies for Assessing Autistic-Like Behaviors in Mice07:38

Strategies for Assessing Autistic-Like Behaviors in Mice

Published on: September 20, 2024

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...